PMA device
Dermagraft
Shire Regenerative Medicine · Dressing, Wound And Burn, Interactive (MGR, Class III) · First FDA decision Sep 28, 2001, newest Apr 18, 2012BurnsChronic wounds and ulcers
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
6
Naming "Dermagraft"
MAUDE reports
3
Brand "Dermagraft", since 2015
PubMed studies
73
Mentioning "Dermagraft"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Dermagraft
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- DERMAGRAFTPMA supplement
P000036-S008 · Decided Apr 18, 2012 · 36 days after receipt · Normal 180 Day Track No User Fee
Device type: Dressing, wound and burn, interactive (MGR) · General & Plastic Surgery
- DERMAGRAFTPMA
P000036 · Decided Sep 28, 2001 · 399 days after receipt
Device type: Dressing, wound and burn, interactive (MGR) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Dermagraft", any status and sponsor, newest update first.
- VA MERIT: A Comparative Efficacy Study: Treatment of Non-Healing DiabeticPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT01450943 · 120 participants · Start Oct 1, 2011 · Primary completion Dec 14, 2017
Device: SECONDARY dressing gauze and tape; Dermagraft and 1 more · For: Diabetic Foot Ulcer
Sites: Sacramento, California
- Pivotal Trial of Dermagraft(R) to Treat Venous Leg UlcersPivotal-lookingCompleted
OrganogenesisNot on our public-company list
NCT00909870 · 537 participants · Start Jun 2009 · Primary completion May 2011
Device: Dermagraft(R); Profore · For: Venous Leg Ulcer
Sites: Mobile, Alabama; Phoenix, Arizona; Tucson, Arizona · 70 sites in all
- Dermagraft(R) for the Treatment of Patients With Diabetic Foot UlcersPivotal-lookingCompleted
OrganogenesisNot on our public-company list
NCT01181440 · 281 participants · Start Sep 1994 · Primary completion Jan 1997
Device: Dermagraft(R) · For: Diabetic Foot Ulcer
Sites: San Antonio, Texas
3 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Dermagraft", and for the whole product code for context.
This brand
3 reports: 0 malfunction, 3 injury, 0 death
Whole product code MGR
11 reports: 1 malfunction, 9 injury, 0 death
Newest reports for this brand
- DERMAGRAFTInjury
2028403-2019-00001 · Received Mar 19, 2019 · Event dated Dec 13, 2018
Device type: Cultured Human Cell Skin Dressing (PFC)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hypersensitivity/Allergic reaction
- DERMAGRAFTInjury
2028403-2019-00002 · Received Mar 19, 2019 · Event dated Jan 8, 2019
Device type: Cultured Human Cell Skin Dressing (PFC)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hypersensitivity/Allergic reaction
- DERMAGRAFTInjury
2028403-2019-00003 · Received Mar 19, 2019 · Event dated Feb 21, 2019
Device type: Cultured Human Cell Skin Dressing (PFC)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hypersensitivity/Allergic reaction
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Smith and Nephew Wound Management (La Jolla)
Z-0904-03 · Started May 2, 2003 · Posted by FDA Jun 4, 2003
Reason given: Did not meet finished device specifications for the DNA criteria.
Cause as FDA categorized it: Other · Device type: Dressing, Wound And Burn, Interactive (MGR)
Published research
The most relevant PubMed records for "Dermagraft"[tiab]. The summary above synthesizes these.
- Commercial considerations in tissue engineering.
Mansbridge J · J Anat · 2006Review
- Treatment of venous leg ulcers with Dermagraft.
Omar AA, Mavor AI, Jones AM, et al. · Eur J Vasc Endovasc Surg · 2004Clinical Trial, Randomized Controlled Trial
- Dermagraft treatment of diabetic ulcers.
Eaglstein WH · J Dermatol · 1998Review
- 'Dermagraft': a new treatment for diabetic foot ulcers.
Edmonds ME, Foster AV, McColgan M · Diabet Med · 1997Editorial
- Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers.
Gentzkow GD, Iwasaki SD, Hershon KS, et al. · Diabetes Care · 1996Clinical Trial, Comparative Study
- Dermagraft: Use in the Treatment of Chronic Wounds.
Hart CE, Loewen-Rodriguez A, Lessem J · Adv Wound Care (New Rochelle) · 2012
- Skin substitutes to enhance wound healing.
Mansbridge J · Expert Opin Investig Drugs · 1998
- Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the french context.
Allenet B, Parée F, Lebrun T, et al. · Diabetes Metab · 2000
- Dermagraft, a bioengineered human dermal equivalent for the treatment of chronic nonhealing diabetic foot ulcer.
Marston WA · Expert Rev Med Devices · 2004Review
- Update on tissue-engineered biological dressings.
Ehrenreich M, Ruszczak Z · Tissue Eng · 2006Review
- Dermagraft in the treatment of diabetic foot ulcers.
Bowering CK · J Cutan Med Surg · 1998Review
- The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial.
Marston WA, Hanft J, Norwood P, et al. · Diabetes Care · 2003Clinical Trial, Comparative Study
Other devices of this type
Also filed under product code MGR.
- ApligrafOrganogenesis, Inc. · PMA 2013
- TranscyteShire Regenerative Medicine · PMA 2004
- Integra Dermal Regeneration TemplateIntegra Lifesciences Corp. · PMA 2017
- Transcyte Human Fibroblast-Derived Temporary Skin SubstituteShire Regenerative Medicine · PMA 2011
- Apilgraf(Graftskin)Organogenesis, Inc. · PMA 2002
- Orcel Bilayered Cellular MatrixForticell Bioscience · PMA 2001
- Transcyte/Human Fibroblast Derived Temporary Skin SubstituteShire Regenerative Medicine · PMA 2001
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.